Two Pore Guys Collaborating With UCSF on Point-of-Care Liquid Biopsy

Jan 06, 2017

|

NEW YORK (GenomeWeb) – Santa Cruz, California-based Two Pore Guys said today that it is collaborating with oncologists at the University of California, San Francisco to develop a liquid biopsy assay. The UCSF team plans to evaluate Two Pore Guys' handheld nanopore platform for detecting circulating tumor DNA, and specifically, for detecting a KRAS mutation from blood and urine samples.

Andrew Ko, a professor of hematology and oncology and gastrointestinal cancer specialist at the UCSF Helen Diller Family Comprehensive Cancer Center, will lead the study.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Breaking News

Featured White Papers

Analysis of Inflammatory Plasma Biomarkers in Cancer Patient Samples using Simoa CorPlex Human Cytokine Panel 1

A High-Performance Solution Combining CleanPlex OncoZoom Cancer Hotspot Panel and SOPHiA AI for Rapid Characterization of Somatic Mutations

Oct

24

Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

Nov

14

Featured Webinar

High-Performance Variant Detection in Somatic Cancer Testing with an Integrated NGS Solution

This webinar will discuss some of the issues laboratories face when transitioning to next-generation sequencing, and the key features to be considered for a successful implementation in routine testing.

Dec

02

Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Menu